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 Summary : 
This study comprised 850 subjects from three villages in the Gezira area in the central regain of the 
Sudan. Faeces and urine specimens collected from the above subjects were examined for Schistosoma 
mansoni and S.heamatobium. One hundred and six individuals were confirmed positive, 49 (46.2%) with 
S.mansoni, 50 (47.2%) were infected with  S.heamtobium and 7 ( 6.6%) with mixed infection. Of the 106 
serum samples obtained from schistosoma-infected subjects and 100 serum samples from control subjects 
were tested by ELISA, 33 (31.1%) and 4 (4%) were found reactive for HCV antibodies respectively. These 
results showed strong association between schistosomaisis and HCV, which may suggest that schistosoma 
infection is a cofactor in HCV infection in patients with Bilharsiasis. A further study of large population 
size is highly recommended in order to draw a conclusion in the association between HCV and schistosoma 
infections. 
 
Introduction: 
 Hepatitis C Virus is a major public health problem worldwide, affecting several hundred 
millions people with considerable morbidity and mortality in humans1. The virus may rarely cause acute 
symptomatic infection; however it is characterized by its high level of chronicity, which may predispose 
the patient to liver cirrhosis and eventually to hepatocellular carcinoma. 2,3  It has been clearly indicated that 
schistosoma infection progresses to chronic liver disease. Various studies carried out globally suggested a 
role for schistosomaisis in the pathogenesis of HCV and the sequalae that follow 4.5. In Egypt, the origin of 
the HCV epidemic has been attributed to intravenous schistosomiasis treatment in rural areas in the 1960s 
to 70s. HCV antibody prevalence was 18.5% (448/2,425) 6 . Also,in Egypt proved to be the prevalence of 
HCV antibodies increased from 2.7% in those <20 years of age to more than 40% in males aged 40-54 
years7. 
In Kingdom of Saudi Arabia, among 39 cases of  bilharziasis  patients 7(17.9%) were found to have 
evidence of HCV antibodies8 
 In Gezira state of central Sudan, the prevalence  of HCV reactive antibodies were 2.2% detected 
among schistosomiasis cases9  
The aim of this study is to explore the association of S.mansoni and S.haematobium infections with 
HCV. And to establish the seroprevalence of HCV in the study area, as well as age as a risk factors in HCV 
and schistosoma-infection. 
 
Material and Methods: 
The study area comprises three villages in the Gezira State, 187 kilometers south of khartoum,  
namely Wad El Fadni, El Kidawa, and El–Tadamon Villages. 
The total study population was 850 subjects distributed as follows:300 khalwa school students from Wad 
El Fadni, 400 subjects from El kidawa (El Maktab and El Hilla), 150 school children from El Tadamon. 
Faeces and urine samples were obtained from all participants and examined for Schistosoma 
mansoni ova. A total of 106 subjects were found to be positive for S. manoni by keto-Katz method. Blood 
specimens were collected from schistosoma-positives subjects, sera were separated and stored at – 20 DC 
till time for testing. 
Indirect IgG ELISA (Novum Diagnostic a GMBH) was performed on the 106 test serum samples 
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and 100 sera from reference control subjects those who were negative for schistosoma4. The mean 
absorbance value (MA) of each test and control serum was calculated. The cut-off value (Co) was calculated 
as follows: Co = MA + 0.4. 
 
 
 
Results: 
In El – Kedawa- El hilla, 200 subjects age 9-25 years (mean age 14 years) were examined, 16 (80%) 
were positive for S.mansoni, 4 (2%) for S. haematobzum. The prevalence of  HCV antibodies was 8 (50%) 
in S. mansoni,1 (25%) in S. haematobium Patients. 
In El Kidawa-El Maktab, 200 subjects aged 11 to 67 years, (mean age 23 years) were examined, 13 (6.5%) 
were positive for S. mansoni, 8 (4%) for S. haematobium, and 1 (0.5%) with mixed. S. mansoni and S. 
haematobium  Infection. The Prevalence of HCV antibodies was 5 (38.5%) in S.mansoni.3 (37.5%) in 
S.haematobium patients. The subjects with mixed infection were all positive for HCV.
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Table (1) Distribution of  Schistosomiasis by location: 
Location No. of 
examin
ed 
subject
s 
No. of infected subjects To
tal 
% 
S.m
ans
oni 
% S.hae
matobi
um 
% S.ma
ns & 
S.hea
t 
% 
Geneid-
kediwa-
Hilla 
200 16 8.00 4 2.00 0 0 20 10.
00 
Geneid 
Elmaktab 
200 13 6.5 8 4.00 1 0.5 22 11.
00 
Wad 
Elfadni 
300 14 4.66 28 9.33 2 0.6
6 
44 14.
65 
Total 850 49 5.76 50 5.88 7 0.8
2 
10
6 
12.
47 
 
Table (2) Prevalence of hepatitis C virus antibodies in sera of infected subjects with Schistosomiasis 
Location Infected with 
Schistosomiasis 
HCV antibodies 
Negative positive 
No % No % 
Geneid-kediwa-El 
Hilla 
20 11 55 9 45 
GENEID 
ELMAKTAB 
22 13 59.0
9 
9 40.90 
ELTADAMON 20 19 95 1 5 
WAD ELFADNI 44 30 68.1
8 
14 31.81 
TOTAL 106 73 68.8
6 
33 31.13 
 
 Table (3) Prevalence of hepatitis C virus antibodies in sera of infected subjects with Schistosomiasis 
Location Total infected 
with 
Schistosomiasis 
HCV antibodies 
positiv
e 
% Negati
ve 
% 
Geneid-kediwa-El 
Hilla 
16 8 50 8 50 
GENEID 
ELMAKTAB 
13 5 38.5 8 61.5 
ELTADAMON 6 1 16.6 5 83.3 
WAD ELFADNI 14 4 28.5 10 71.5 
TOTAL 49 18 36.7 34 63.3 
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Table (4) Prevalence of hepatitis C virus antibodies in sera of infected subjects with Schistosomiasis 
Location Total infected with 
Schistosomiasis 
HCV antibodies 
positive % Negati
ve 
% 
Geneid-kediwa-El 
Hilla 
4 1 25 3 75 
GENEID 
ELMAKTAB 
8 3 37.5 5 62.5 
ELTADAMON 10 0 0 10 100 
WAD ELFADNI 28 10 35.7 18 64.3 
TOTAL 50 14 28 36 72 
 
Table (5) Prevalence of hepatitis C virus antibodies in sera of infected subjects with Schistosomiasis 
Location Total infected with 
Schistosoma mansoni 
& haematobium 
HCV antibodies 
positi
ve 
% Negati
ve 
% 
Geneid-kediwa-
El Hilla 
0 0 0 0 0 
GENEID 
ELMAKTAB 
1 1 100 0 0 
ELTADAMON 4 0 0 4 100 
WAD ELFADNI 2 0 0 2 100 
TOTAL 7 1 14.3 6 85.7 
 
 
 Table (6) Prevalence of hepatitis C virus antibodies in sera of infected subjects with Schistosomiasis 
HCV Total infected with 
S.mansoni 
HCV 
antibodies 
Total 
No % No % 
Positive 33 31.1 4 4.0 37 
Negative 73 68.9 96 96 169 
Total 106 100.0 100 100 206 
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In El- Tadamon, 150 school children aged 10 to 15 years (mean age 12 years) were examined, 6 
(4%) were positive for S.mansoni. 10 (6.6%) for S.haematobium and 4 (2.6%) had mixed infection. The 
prevalence of HCV antibodies were 1 (16.6%) in S.manasoni-infected subjects. 
In Wad El.Fadni, 300 Khalawi students age 10 to 70 years.( mean age 17 years) were examined for 
schistosoma, 14 (4.6%) were positive for S.mansoni, 28 (9.3%) for S.heamatobium and, 2 (0.6%) had mixed 
infection. The Prevalence of HCV antibodies was 4 (28.5%) in S.mansoni, 10 (35.7%) in S.haematobium 
subjects (Tables 1-6).out of 100 schistosoma, non-infected subjects, 4 were positive for HCV antibodies. 
All anti- HCV reactive samples were repeatedly tested. 
Discussion: 
The infection level of S.mansoni and S.haematobium in this study population appeared to be overall 
similar (5.67% and 5.88%), but is remarkably high in Wad El Fadni Village, which is located in the old 
Gezira Scheme, West of the Blue Nile (Table1).  
This is probably due to the geographic location of Wad El Fadni in the old Gezira Scheme, which 
already known to be hyperendemic for schistosomaisis. 
The overall prevalence of anti-HCV in schislosomaisis patients (31.1%) is considered high in comparison 
to that in the control group. The high incidence of anti-HCV in the two parts of El-kidiwa village (40.9%) 
compared to the incidence in El-Tadamon (4%) is difficult to justify. (Table2). However, the demographic 
factor may be the reason, 
The average incidence of HCV antibodies among S.mansoni patients is high (63.3%) , however the 
incidence (83.3%) in El T’adamon is even higher, that may be due to the small number of samples tested 
(Table3). 
The incidence of HCV in subjects with S.haematobium is remarkably high (100%) in El-Tadomon, however 
the overall incidence of anti-HCV is slightly higher (72%) than that in S, mansion infected subjects 
(Table4). 
The seroprevalence of HCV in individuals co-infected with both schistosoma species is significantly 
high (100%) in El Tadoman and Wad El Fadni Villages. The over all incidence of HCV in this mixed 
population is higher (85.7%) than in those infected with a single species of schistosoma. This is clearly due 
to the small number of samples tested (Tables 5) . 
The present study support other studies indicating that, the HCV. incidence is higher in schistomaisis 
patents than those non-infected with schistosoma, with some variation in the prevalence rate. In a study 
carried in the Nile Delta Region of Egypt, where HCV prevalence is the highest in the world “ The HCV 
incidence is fairly comparable (41%) with that in the present the study (31.8%)5-9. 
An other study among the Brazilian population infected with S.mansoni showed a lower level (24%) 
of HCV seroprevalence0 10, 
In regions of Africa, where malaria is endemic, malarial immune complexes may contribute to anti-
HCV false positivity, which is probably attributable to anti-nuclear and other autoantibodies 11. False 
positivity has been found in bot weakly and strongly reactive sera12. This is expected in an endemic malarial 
African country such as the Sudan 13. 
Our results were based on ELISA screening only (Other assays should have been performed). The 
reactive specimens should be retested by a supplementary assay such as recombinant immune blot assay 
(RIBA) and confirmed by polymerase chain reaction (PCR). However, assay other than ELISA are not 
available in the Gezira State, which justifies the use of ELISA only. 
On the whole this study highlighted the importance of HCV pathogenecity and its association with 
schistosomasis in Gezira region, and therefore warranted further research in the relationship between HCV 
and schistosomaisis. 
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